ArticlebioRxiv : the preprint server for biology2025
Programmable cell differentiation in budding yeast uncouples reproductive and metabolic tasks.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
High-yield biomanufacturing requires large cell populations and a mechanism for directing metabolic resources towards product synthesis. However, the resources that support population growth are the same as those that drive productivity, creating a conflict that limits production yields. To overcome this fundamental limitation, we apply the principle of division of labor to separate reproductive and metabolic tasks into distinct cell types within an isogenic Saccharomyces cerevisiae culture. We introduce MiSTY (Microbial Stem Cell Technology in budding Yeast), a genetic platform that exploits natural asymmetric cues to control cell differentiation. Leveraging bud cell-specific transcription, a sequential series of recombinase-based genetic circuits generates Activated Stem Cells (ASCs) that divide asymmetrically into two cell types: bud cells that terminally differentiate into Factory Cells (FCs) and mother cells that remain self-renewing ASCs. Time-lapse microscopy demonstrated 100% differentiation fidelity across 97 cell divisions. Phenotypic and genotypic analyses showed that stem cell populations could be converted to over 95% FCs within 24 generations. By converting FCs into leucine auxotrophs, we inhibited FC proliferation while allowing continued ASC division, demonstrating complete uncoupling of cell growth from product synthesis. Because they continuously generate healthy new FCs, MiSTY cultures maintain high levels of productivity even under conditions that severely impair the growth and biosynthetic capacity of metabolically exhausted factory cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.